New biomarkers in pain management; Clavis Pharma looks for AML biomarkers;

> New biomarkers in pain management may speed drug development and reduce costs. Item

> Norway's Clavis Pharma has received a $2.5 million grant from The Research Council of Norway to develop a hENT1 biomarker assay for targeted therapy of AML patients. Clavis release

> Immunological abnormalities are potential biomarkers in Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis. Abstract

> In 2010, the total global market for biomarkers was an estimated $13.5 billion, according to a market report. Release

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.